Pulmonary vaccine delivery.
This review will discuss developments in the field of pulmonary vaccine delivery. The possibilities of adopting aerosol-generation technology and specific pharmaceutical formulations for the purpose of pulmonary immunization are described. Aerosol-generation systems might offer advantages with respect to vaccine stability and antigenicity. Adjuvants and their inclusion in vaccine-delivery systems are described. Other formulation components, such as surfactants, particulate systems and dispersion of the aerosols are detailed in this paper. The noninvasive, relatively safe and low-cost nature of pulmonary delivery may provide great benefits to the public health vaccination campaign.
Lu
Dongmei
D
Division of Molecular Pharmaceutics, School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA. ludm@email.unc.edu
Hickey
Anthony J
AJ
D000276:Adjuvants, Immunologic / Q000008:administration & dosage; D000280:Administration, Inhalation; D000336:Aerosols; D000818:Animals; D002626:Chemistry, Pharmaceutical; D004337:Drug Carriers / Q000737:chemistry*; D004339:Drug Compounding; D016503:Drug Delivery Systems / Q000295:instrumentation; D004355:Drug Stability; D018014:Gene Transfer Techniques; D006801:Humans; D018928:Immunity, Mucosal; D036501:Metered Dose Inhalers; D009330:Nebulizers and Vaporizers; D010316:Particle Size; D011208:Powders; D013501:Surface-Active Agents / Q000737:chemistry; D013678:Technology, Pharmaceutical; D014611:Vaccination / Q000295:instrumentation / Q000379:methods* / Q000639:trends; D014612:Vaccines / Q000008:administration & dosage* / Q000737:chemistry* / Q000235:genetics / Q000276:immunology
D000276:Adjuvants, Immunologic; D000336:Aerosols; D004337:Drug Carriers; D011208:Powders; D013501:Surface-Active Agents; D014612:Vaccines